Product Description
GMP+DMF
AI Product Description
*The following content is generated by AI and is for reference only.
Voriconazole, identified by its Chemical Abstracts Service (CAS) Registry Number 137234-62-9, is a potent second-generation triazole antifungal agent widely utilized in modern clinical practice. Its molecular formula is C16H14F3N5O, reflecting a complex structure containing fluorine and nitrogen atoms that contribute to its high specificity against fungal pathogens. This medication functions primarily by inhibiting the enzyme lanosterol 14α-demethylase, a critical component of the cytochrome P450 system in fungi. By blocking this enzyme, voriconazole disrupts the synthesis of ergosterol, an essential structural component of fungal cell membranes, leading to increased membrane permeability and ultimately fungal cell death.
Clinically, voriconazole serves as a first-line treatment for invasive aspergillosis, a life-threatening infection caused by Aspergillus species, particularly in immunocompromised patients such as those undergoing chemotherapy or organ transplantation. Beyond aspergillosis, it demonstrates broad-spectrum efficacy against various other resistant fungi, including Candida species (including some fluconazole-resistant strains), Fusarium, Scedosporium, and Basidiobolus. Its administration routes include intravenous infusion and oral tablets, offering flexibility in managing severe systemic infections where rapid therapeutic levels are required. The drug exhibits excellent tissue penetration, reaching effective concentrations in the lungs, brain, and eyes, which makes it invaluable for treating disseminated or central nervous system fungal infections.
Despite its therapeutic success, voriconazole requires careful monitoring due to its narrow therapeutic index and potential for significant drug-drug interactions mediated by cytochrome P450 enzymes. Common side effects may include visual disturbances, skin rash, and hepatotoxicity. Genetic polymorphisms affecting metabolism can also lead to variable plasma concentrations, necessitating therapeutic drug monitoring in many cases. Overall, voriconazole represents a cornerstone in the management of serious invasive fungal diseases, bridging the gap between older azoles and newer echinocandins with its unique mechanism of action and robust spectrum of activity.